



November 22, 2013

AnGes MG, Inc.

**Completion of IRB Review for the Small-scale Study of Collategene®**

AnGes MG, Inc. (AnGes) today announced that its subsidiary, AnGes, Inc., (Maryland, United States [US]) has received a notice concerning review completion and acceptance of the protocol for the small-scale clinical study of Collategene® by the Institutional Review Board (IRB) at the trial site.

The necessary environment to conduct the small-scale study is hereby prepared and its start will be a big step toward the global development of Collategene® as a treatment for critical limb ischemia. The AnGes Group will start the global Phase III study of Collategene® following the initiation of the small-scale study.

The global Phase III study is a double-blinded study and the results are only accessible at the completion of the trial. On the other hand, the small-scale study is an open-label study and has the same design and endpoints as the Phase III trial. Thus, the small-scale study enables AnGes to access and analyze the progress in patients after the administration of Collategene® while the study is ongoing. AnGes will utilize findings from the small-scale study in proceeding with the Phase III study.

An IRB is a committee formed at an institution at which a clinical trial will take place. The IRB comprehensively reviews the human rights and safety of study participants. The IRB is an independent committee that consists of specialists as well as non-specialists of medical science.

The aim of the AnGes Group is to deliver the treatment to patients with critical limb ischemia who currently have no treatment options available. AnGes is advancing necessary preparations to commence the global Phase III study of Collategene®.

This event has no effect on business performance for the fiscal year 2013.

###

*Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.*

AnGes MG, Inc.  
Corporate Communications  
TEL: +81-3-5730-2641, FAX: +81-3-5730-2635  
<http://www.anges-mg.com>